Meeting
2022 ASCO Quality Care Symposium
Patterns of olanzapine prescribing for those receiving highly emetogenic chemotherapy.
Authors
Daniel S Childs
Mayo Clinic, Rochester, MN
Daniel S Childs, David A Helfinstine, Lindsey R. Sangaralingham, Jacob Orme, Ciara Catherine O'Sullivan, Charles L. Loprinzi, Kathryn Jean Ruddy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 232)
DOI
10.1200/JCO.2022.40.28_suppl.232
Abstract #
232
Poster Bd #
B29
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.
First Author: Ashley Bowen
Poster
2020 ASCO Quality Care Symposium
Use of antiemetic prophylaxis and oral breakthrough medication for highly emetogenic chemotherapy (HEC) in a large community oncology network.
First Author: Garrett Young
Poster
2018 ASCO Quality Care Symposium
Enhanced compliance with appropriate antiemetic prescribing guidelines by utilizing a medically integrated pharmacy antiemetic therapeutic interchange protocol.
First Author: Lalan S. Wilfong
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas